All companies
Royalty Pharma logo

What smart money is saying about Royalty PharmaUnited States flag

RPRX · Healthcare · Biotechnology · Market cap $17.46B

1 fund in our archive has pitched Royalty Pharma — most recently Cooper Investors Global Endowment in September 2025.

Company profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

1
Reported positions
0
Bought
0
Sold
3
Letters

Position history

Between Q3 2025 and Q2 2026, 1 fund letter reported a position in Royalty Pharma, with no move described.

Fund letters reporting a position in Royalty Pharma, by quarter
QuarterLettersBoughtSoldTheses
Q2 20261000
Q3 20250001

Fund activity · 1 position

Also mentioned · 1

These funds discuss Royalty Pharma — as a competitor, benchmark or comparable — without disclosing a position in it.

Fund coverage · 1 thesis

Read every full thesis on Royalty Pharma

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger